Zeo ScientifiX (ZEOX) joins Cytora and Made Scientific in U.S. stem cell therapy pact

Rhea-AI Filing Summary

Zeo ScientifiX, Inc. reported that it has entered into a comprehensive strategic partnership with Cytora Therapeutics Ltd. and Made Scientific, Inc. The collaboration focuses on advancing and commercializing Cytora’s novel allogeneic, off-the-shelf human oral mucosal stem cell therapy in the United States.

Cytora is described as a clinical-stage biotechnology company based in Israel, while Made Scientific is a U.S.-based cell therapy contract development and manufacturing organization. The joint press release outlining additional details of the partnership is attached as Exhibit 99.1.

Insights

Biotech partnerships and strategy analyst

Zeo ScientifiX adds a three-way stem cell therapy partnership focused on the U.S. market.

The company announced a comprehensive strategic partnership with Cytora Therapeutics, a clinical-stage Israeli biotechnology firm, and Made Scientific, a U.S.-based cell therapy contract development and manufacturing organization. The collaboration centers on Cytora’s allogeneic, off-the-shelf human oral mucosal stem cell therapy, with an explicit focus on advancing and commercializing this therapy in the United States.

The structure implies that Cytora contributes the clinical-stage stem cell asset, while Made Scientific provides development and manufacturing capabilities. Zeo ScientifiX positions itself within this ecosystem as part of a multi-party effort to move the product toward U.S. commercialization, but no financial terms, timelines, or development milestones are disclosed in the excerpt.

The attached press release (Exhibit 99.1) is intended to provide further detail, yet those specifics are not included here. The actual impact on Zeo ScientifiX will depend on the terms of the partnership and the clinical and regulatory progress of Cytora’s therapy, which are not described in this text.

false 0001557376 0001557376 2026-01-07 2026-01-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 7, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada		000-55008		47-4180540
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3321 College Avenue, Suite 246 Davie, Florida		33314
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “Zeo,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

Item 8.01 Other Events.

On January 7, 2026, Zeo issued a joint press release together with Cytora Therapeutics Ltd. (“Cytora”), a clinical-stage biotechnology company based in Israel developing allogeneic, stem cell therapies, and Made Scientific, Inc. (“Made Scientific”), a leading U.S.-based cell therapy contract development and manufacturing organization, announcing a comprehensive strategic partnership among Zeo, Cytora and Made Scientific to advance and commercialize Cytora’s novel allogeneic, off- the- shelf, human oral mucosal stem cell therapy in the U.S.

A copy of the press release is included as Exhibit 99.1 to this Report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated January 7, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 7, 2026	ZEO SCIENTIFIX, INC.
	By:	/s/ Ian T. Bothwell
		Ian T. Bothwell Chief Executive Officer and Chief Financial Officer

2

FAQ

What did Zeo ScientifiX (ZEOX) announce in its latest 8-K?

Zeo ScientifiX announced a comprehensive strategic partnership with Cytora Therapeutics Ltd. and Made Scientific, Inc. to advance and commercialize Cytora’s allogeneic, off-the-shelf human oral mucosal stem cell therapy in the United States.

Who are the partners working with Zeo ScientifiX (ZEOX) on the stem cell therapy?

The partners are Cytora Therapeutics Ltd., a clinical-stage biotechnology company based in Israel developing allogeneic stem cell therapies, and Made Scientific, Inc., a leading U.S.-based cell therapy contract development and manufacturing organization.

What type of therapy is covered by Zeo ScientifiX’s new strategic partnership?

The partnership focuses on Cytora’s novel allogeneic, off-the-shelf, human oral mucosal stem cell therapy, with the goal of advancing and commercializing it in the U.S. market.

Where can investors find more details about Zeo ScientifiX’s partnership with Cytora and Made Scientific?

More details are provided in the joint press release dated January 7, 2026, which is included as Exhibit 99.1 to the report and incorporated by reference.

Does the Zeo ScientifiX (ZEOX) filing include financial terms of the partnership?

The excerpt describes the partnership’s purpose and the parties involved but does not include any specific financial terms or milestones related to the collaboration.

What role does Made Scientific play in Zeo ScientifiX’s new collaboration?

Made Scientific, Inc. is identified as a leading U.S.-based cell therapy contract development and manufacturing organization, suggesting it will provide development and manufacturing support for Cytora’s stem cell therapy within the partnership.